With the potential to transform treatment for severe viral infections, our pipeline sets us on a clear and focused path towards rapid clinical product development and commercialization.

RNA Viruses

To address a variety of infections caused by RNA viruses, we are advancing product candidates that are designed to directly inhibit viral replication by blocking the synthesis of viral RNA. Derived from our nucleotide prodrug platform, these product candidates are designed to have advantageous characteristics and features including: enhanced antiviral activity and selectivity, well tolerated profiles, convenience of once or twice daily oral administration and efficient, scaleable and reproducible manufacturing, as well as long shelf life for potential stockpiling.


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), colloquially known as the coronavirus, is a positive single-stranded RNA virus that causes the coronavirus disease 2019, known as COVID-19, a highly contagious acute respiratory illness with life-threatening risks for certain patients.

Learn More

A common, often debilitating, mosquito borne infection annually affecting millions of people worldwide, where no approved pharmaceutical treatment is available.

Learn More
Hepatitis C

A blood-borne liver infection, where a substantial unmet medical need remains for short duration and tolerable oral therapy, for large populations of patients, including those with compensated and decompensated cirrhosis, HIV co-infection, and patients at increased risk for adverse events or drug interactions with protease inhibitor-based regimens.

Learn More
Respiratory Syncytial Virus (RSV)

A common lung and respiratory tract infection affecting young children and older adults, for which no approved viral-specific pharmaceutical treatment is available.

Learn More

Atea’s Deep Antiviral Pipeline

Atea is advancing oral product candidates that are designed to be potent and selective, including nucleos(t)ide analogs being developed as either monotherapy or in combination with other antiviral agents. Each of the nucleos(t)ide analogs Atea is currently advancing in clinical development, specifically bemnifosbuvir (AT-527) and AT-752, have been derived from Atea’s proprietary nucleotide platform. These product candidates are designed to inhibit the enzymes central to viral replication while avoiding toxicity to host cells.

Expanded Access Policy